Impax Laboratories, Inc. (IPXL)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paul M. Bisaro
Employees:
1,495
30831 HUNTWOOD AVENUE, HAYWARD, CA 94544
510-240-6000

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture, and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments. The Impax Generics segment concentrates on the development manufacture, sale and distribution of generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Impax Specialty Pharma segment engages in the development of proprietary brand pharmaceutical products. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.35 Billion Shares Outstanding73.758 Million Avg 30-day Volume 871.017 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-6.97
Price to Revenue0.0 Debt to Equity13.2388 EBITDA128.076 Million
Price to Book Value23.5823 Operating Margin0.0 Enterprise Value2.09 Billion
Current Ratio1.642 EPS Growth0 Quick Ratio0.94
1 Yr BETA 0.82 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-191.7609 Free Cash Flow to Firm (FCFF) TTM 440.589 Million Free Cash Flow to Equity (FCFE) TTM37.188 Million
Altman Z-Score0.3714
View SEC Filings from IPXL instead.

View recent insider trading info

Impax Laboratories, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IPXL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IPXL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2018-05-08 by VERGIS JANET S.
  • 4: filed on 2018-05-08 by TERRERI PETER R
  • 4: filed on 2018-05-08 by PENDERGAST MARY K
  • 4: filed on 2018-05-08 by CHAO ALLEN
  • 4: filed on 2018-05-08 by BUCHI J KEVIN
  • 4: filed on 2018-05-08 by BENET LESLIE Z
  • 4: filed on 2018-05-08 by BURR ROBERT L
  • 4: filed on 2018-05-08 by NORNHOLD JEFFREY
  • 4: filed on 2018-05-08 by SCHLOSSBERG MARK A
  • 4: filed on 2018-05-08 by NESTOR MICHAEL

    • Events (8k)

  • 8-K: filed on 2018-05-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-04-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-03-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-03-19:
    Item 8.01: Other Events
  • 8-K: filed on 2018-03-07:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2018-03-05:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2018-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-24:
    Item 8.01: Other Events
  • 8-K: filed on 2018-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CHAO ALLEN

    • Director
    		 No longer subject to file 2018-05-04 0

    PENDERGAST MARY K

    • Director
    		 No longer subject to file 2018-05-04 0

    NESTOR MICHAEL PRESIDENT, IMPAX SPECIALTY

    • Officer
    		 No longer subject to file 2018-05-04 0

    BUCHI J KEVIN

    • Director
    		 No longer subject to file 2018-05-04 0

    BISARO PAUL PRESIDENT AND CEO

    • Officer
    • Director
    		 No longer subject to file 2018-05-04 0

    TERRERI PETER R

    • Director
    		 No longer subject to file 2018-05-04 0

    BENET LESLIE Z

    • Director
    		 No longer subject to file 2018-05-04 0

    BURR ROBERT L

    • Director
    		 No longer subject to file 2018-05-04 0

    SCHLOSSBERG MARK A SVP AND GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2018-05-04 0

    REASONS BRYAN M. CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2018-05-04 0

    BOOTHE DOUGLAS PRESIDENT, GENERICS DIVISION

    • Officer
    		 No longer subject to file 2018-05-04 0

    VERGIS JANET S.

    • Director
    		 No longer subject to file 2018-05-04 0

    NORNHOLD JEFFREY SVP, TECHNICAL OPERATIONS

    • Officer
    		 No longer subject to file 2018-05-04 0

    BIERLY RICK

    • Director
    		 9,270 2017-05-16 0

    WILKINSON GEORGE FRED CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 429,237 2016-04-29 0

    FLEMING NIGEL

    • Director
    		 8,200 2015-08-31 0

    MARKBREITER MICHAEL

    • Director
    		 8,200 2015-08-28 0

    HSU LARRY

    • Director
    		 2,886,448 2015-05-12 0

    BEN-MAIMON CAROLE PRESIDENT, GLOBAL PHARM.

    • Officer
    		 85,914 2014-05-14 0

    KOCH ARTHUR A JR EVP, FINANCE, AND CFO

    • Officer
    		 142,415 2012-05-26 0

    HILDENBRAND CHARLES V SVP, OPERATIONS

    • Officer
    		 35,222 2011-05-26 0

    MENGLER CHRISTOPHER

    • FORMER DIVISION PRESIDENT
    		 No longer subject to file 2010-11-05 0

    OH KIM SUN

    • Director
    		 30,679 2009-11-11 0

    EDWARDS BARRY R

    • Director
    		 841,901 2006-12-31 0

    HSIAO CHARLES

    • Director
    		 4,104,456 2006-12-31 0

    DOLL DAVID S EXEC.VP, COMMERCIAL OPERATIONS

    • Officer
    		 117,279 2006-12-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments